FDA Approves VIGABATRIN — Hikma Pharmaceuticals USA Inc

Hikma Pharmaceuticals USA Inc. received FDA approval for its generic oral version of Vigabatrin in August, a move expected to bolster the company's anticonvulsant portfolio and drive incremental sales growth by providing a more cost-effective treatment option.